FLT3 and acute myeloid leukemia: Surprisingly, preliminary data of a phase III trial of gilteritinib combined with azacitidine vs. azacitidine alone (NCT02752035) in newly diagnosed FLT3-mutated UNFIT AML patients failed to demonstrate a survival benefit for the addition of the FLT3 inhibitor.